Search
Search Results
-
Precision Molecular Pathology of Aggressive B-Cell Lymphomas
Written by experts in the field, Precision Molecular Pathology of Aggressive B-Cell Lymphomascontains the most recent revisions from the 5th Edition...
-
HLA-haploidentical T-cell receptor αβT/B-cell-depleted stem cell transplantation for Fanconi anemia
HLA-haploidentical stem cell transplantation (haplo-SCT) using post-transplant high-dose cyclophosphamide (PT-CY) is an alternative choice when a...
-
Epstein–Barr virus-associated B-cell lymphoproliferative disorder meeting the definition of CAEBV B cell disease: a case report
BackgroundChronic active Epstein-Barr virus infection (CAEBV) is a systemic EBV-positive lymphoproliferative disorder (EBV-LPD) considered to be...
-
Transcriptomic analysis of spleen B cell revealed the molecular basis of bursopentin on B cell differentiation
The bursa of Fabricius, the acknowledged humoral immune organ unique to birds, plays a vital role in B cell development. Bursopentin (BP5) derived...
-
Emerging entities: high-grade/large B-cell lymphoma with 11q aberration, large B-cell lymphoma with IRF4 rearrangement, and new molecular subgroups in large B-cell lymphomas. A report of the 2022 EA4HP/SH lymphoma workshop
Emerging entities and molecular subgroups in large B-cell lymphomas (LBCLs) were discussed during the 2022 European Association for...
-
Novel CAR T cell therapies for patients with large B cell lymphoma
Approximately 60–70% of patients with large B cell lymphoma (LBCL) achieve long-term remission or a cure after initial treatment. However, patients...
-
Axicabtagene ciloleucel treatment is more effective in primary mediastinal large B-cell lymphomas than in diffuse large B-cell lymphomas: the Italian CART-SIE study
Axicabtagene ciloleucel showed efficacy for relapsed/refractory large B-cell lymphomas (LBCL), including primary mediastinal B-cell lymphomas...
-
B-Cell Receptor Repertoire: Recent Advances in Autoimmune Diseases
In the field of contemporary medicine, autoimmune diseases (AIDs) are a prevalent and debilitating group of illnesses. However, they present...
-
Aggressive B cell lymphomas—highlights from ASH 2022
The treatment landscape of aggressive B cell lymphomas has changed substantially in recent years. Several therapeutic agents changed the dogma of...
-
Transdifferentiation of diffuse large B-cell lymphoma to a poorly differentiated neoplasm following CAR T-cell therapy
Chimeric antigen receptor T-cell (CAR-T) therapy is a recent advancement in precision medicine with promising results for patients with relapsed or...
-
Allogeneic CAR-T cells with of HLA-A/B and TRAC disruption exhibit promising antitumor capacity against B cell malignancies
BackgroundAlthough chimeric antigen receptor T (CAR-T) cells have been proven to be an effective way of treating B cell malignancies, a lot of...
-
Targeting CD22 for B-cell hematologic malignancies
CD19-targeted chimeric receptor antigen (CAR)-T cell therapy has shown remarkable clinical efficacy in the treatment of relapsed or refractory (R/R)...
-
Blinatumomab-induced macrophage activating syndrome (MAS) in adult with B-cell acute lymphoblastic leukemia (B-ALL)
Blinatumomab as a single agent has demonstrated superiority over salvage chemotherapy in patients with relapsed and refractory B-cell acute...
-
Granzyme B+ B cells detected by single-cell sequencing are associated with prognosis in patients with intrahepatic cholangiocarcinoma following liver transplantation
B cells possess anti-tumor functions mediated by granzyme B, in addition to their role in antigen presentation and antibody production. However, the...
-
The Future of Natural Killer Cell Immunotherapy for B Cell Non-Hodgkin Lymphoma (B Cell NHL)
Natural killer (NK) cells have played a critical—if largely unrecognized or ignored—role in the treatment of B cell non-Hodgkin lymphoma (NHL) since...
-
Therapeutic options for large B-cell lymphoma relapsing after CD19-directed CAR T-cell therapy
In recent years, chimeric antigen receptor T-cell therapy (CAR T) has revolutionized the treatment landscape for large B cell lymphoma (LBCL),...
-
SPAG6 regulates cell proliferation and apoptosis via TGF-β/Smad signal pathway in adult B-cell acute lymphoblastic leukemia
Adult B-cell acute lymphoblastic leukemia (B-ALL) prognosis remains unsatisfactory, and searching for new therapeutic targets is crucial for...
-
A prognostic score based on B cell and plasma cell densities compared to T cell densities in colorectal cancer
PurposeThe purpose of this study was to compare a B cell/plasma cell–based scoring system to T cell score and evaluate their prognostic value in...
-
Hepatitis B virus–associated diffuse large B cell lymphoma: epidemiology, biology, clinical features and HBV reactivation
Diffuse large B cell lymphoma (DLBCL) is the most common type of lymphoma in adults with high heterogeneity. Recent studies have manifested that the...
-
BTK inhibition limits B-cell–T-cell interaction through modulation of B-cell metabolism: implications for multiple sclerosis therapy
Inhibition of Bruton’s Tyrosine Kinase (BTKi) is now viewed as a promising next-generation B-cell-targeting therapy for autoimmune diseases including...
